144 related articles for article (PubMed ID: 28391353)
21. ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.
Heckler MM; Thakor H; Schafer CC; Riggins RB
FEBS J; 2014 May; 281(10):2431-42. PubMed ID: 24684682
[TBL] [Abstract][Full Text] [Related]
22. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.
Liu B; Wang T; Wang H; Zhang L; Xu F; Fang R; Li L; Cai X; Wu Y; Zhang W; Ye L
J Hematol Oncol; 2018 Feb; 11(1):26. PubMed ID: 29471853
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
Lü M; Ding K; Zhang G; Yin M; Yao G; Tian H; Lian J; Liu L; Liang M; Zhu T; Sun F
Sci Rep; 2015 Mar; 5():8735. PubMed ID: 25736597
[TBL] [Abstract][Full Text] [Related]
25. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
26. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
[TBL] [Abstract][Full Text] [Related]
27. FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression.
Lv Q; Guan S; Zhu M; Huang H; Wu J; Dai X
Technol Cancer Res Treat; 2021; 20():15330338211004935. PubMed ID: 33783288
[TBL] [Abstract][Full Text] [Related]
28. MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3.
Li X; Wu Y; Liu A; Tang X
Biochem Biophys Res Commun; 2016 Sep; 477(4):768-773. PubMed ID: 27363334
[TBL] [Abstract][Full Text] [Related]
29. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X
Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263
[TBL] [Abstract][Full Text] [Related]
30. Hippo/MST blocks breast cancer by downregulating WBP2 oncogene expression via miRNA processor Dicer.
Lim SK; Tabatabaeian H; Lu SY; Kang SA; Sundaram GM; Sampath P; Chan SW; Hong WJ; Lim YP
Cell Death Dis; 2020 Aug; 11(8):669. PubMed ID: 32820148
[TBL] [Abstract][Full Text] [Related]
31. Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen.
Liu H; Lu S; Gu L; Gao Y; Wang T; Zhao J; Rao J; Chen J; Hao X; Tang SC
Cell Physiol Biochem; 2014; 33(2):365-74. PubMed ID: 24557447
[TBL] [Abstract][Full Text] [Related]
32. Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription.
Chen S; Wang H; Li Z; You J; Wu QW; Zhao C; Tzeng CM; Zhang ZM
Br J Cancer; 2018 May; 119(2):182-192. PubMed ID: 29937544
[TBL] [Abstract][Full Text] [Related]
33. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
Shi YF; Lu H; Wang HB
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
[TBL] [Abstract][Full Text] [Related]
34. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells.
Cheng R; Liu YJ; Cui JW; Yang M; Liu XL; Li P; Wang Z; Zhu LZ; Lu SY; Zou L; Wu XQ; Li YX; Zhou Y; Fang ZY; Wei W
Oncotarget; 2017 May; 8(18):30252-30264. PubMed ID: 28415819
[TBL] [Abstract][Full Text] [Related]
35. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
36. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
37. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells.
Li Z; Wang N; Fang J; Huang J; Tian F; Li C; Xie F
Oncol Rep; 2012 Jun; 27(6):1879-86. PubMed ID: 22427054
[TBL] [Abstract][Full Text] [Related]
38. Corylin sensitizes breast cancer cells to overcome tamoxifen resistance by regulating OAS1/miR-22-3p/SIRT1 axis.
Che L; Yang H; Wang D; Liu S
Acta Biochim Pol; 2021 Nov; 68(4):757-764. PubMed ID: 34731560
[TBL] [Abstract][Full Text] [Related]
39. miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.
Ikeda K; Horie-Inoue K; Ueno T; Suzuki T; Sato W; Shigekawa T; Osaki A; Saeki T; Berezikov E; Mano H; Inoue S
Sci Rep; 2015 Aug; 5():13170. PubMed ID: 26255816
[TBL] [Abstract][Full Text] [Related]
40. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
